Cymabay Therapeutics Inc (NASDAQ:CBAY)

4.02
Delayed Data
As of Oct 21
 +0.03 / +0.75%
Today’s Change
3.39
Today|||52-Week Range
9.06
-29.97%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$271.9M

Company Description

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products pipeline include Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Contact Information

CymaBay Therapeutics, Inc.
7575 Gateway Boulevard
Newark California 94560
P:(510) 293-8800
Investor Relations:

Employees

Shareholders

Other institutional51.74%
Mutual fund holders18.29%
Individual stakeholders15.76%

Top Executives

Sujal ShahPresident, Chief Executive Officer & Director
Daniel MenoldVice President-Finance
Charles A. McWherterChief Scientific Officer & Senior Vice President
Dennis D. KimChief Medical Officer
Paul T. QuinlanSecretary & Chief Compliance Officer